MX2024008840A - Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina. - Google Patents

Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina.

Info

Publication number
MX2024008840A
MX2024008840A MX2024008840A MX2024008840A MX2024008840A MX 2024008840 A MX2024008840 A MX 2024008840A MX 2024008840 A MX2024008840 A MX 2024008840A MX 2024008840 A MX2024008840 A MX 2024008840A MX 2024008840 A MX2024008840 A MX 2024008840A
Authority
MX
Mexico
Prior art keywords
oxazepine
pyrido
pyrrolo
tetrahydro
inhibitors
Prior art date
Application number
MX2024008840A
Other languages
English (en)
Spanish (es)
Inventor
Yujia Dai
Jianchun Gong
Patrick Brady
Doherty George A
Vikram Bhat
Judd Andrew S
Souers Andrew J
Yiyun Yu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2024008840A publication Critical patent/MX2024008840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2024008840A 2022-01-21 2023-01-20 Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina. MX2024008840A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263267018P 2022-01-21 2022-01-21
PCT/US2023/060944 WO2023141536A1 (en) 2022-01-21 2023-01-20 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors

Publications (1)

Publication Number Publication Date
MX2024008840A true MX2024008840A (es) 2024-07-25

Family

ID=85382827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008840A MX2024008840A (es) 2022-01-21 2023-01-20 Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2hpirrolo[3',2':5,6]pir ido[2,3-b][1,4]oxazepina.

Country Status (13)

Country Link
US (3) US11964990B2 (cg-RX-API-DMAC7.html)
EP (1) EP4466273A1 (cg-RX-API-DMAC7.html)
JP (2) JP7714811B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240136972A (cg-RX-API-DMAC7.html)
CN (1) CN119053610A (cg-RX-API-DMAC7.html)
AR (1) AR128310A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023210279A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242074A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009334A2 (cg-RX-API-DMAC7.html)
IL (1) IL312709A (cg-RX-API-DMAC7.html)
MX (1) MX2024008840A (cg-RX-API-DMAC7.html)
TW (1) TW202340210A (cg-RX-API-DMAC7.html)
WO (1) WO2023141536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑
CN117820134A (zh) * 2024-01-10 2024-04-05 山东盛安贝新材料有限公司南京分公司 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002032A (es) 2017-08-23 2020-09-17 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de bcl-2.
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
MX2022010410A (es) 2020-02-24 2022-12-07 Guangzhou Lupeng Pharmaceutical Company Ltd Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2.
TW202340210A (zh) * 2022-01-21 2023-10-16 美商艾伯維有限公司 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑

Also Published As

Publication number Publication date
AU2023210279A1 (en) 2024-05-23
JP2025504382A (ja) 2025-02-12
IL312709A (en) 2024-07-01
CA3242074A1 (en) 2023-07-27
AR128310A1 (es) 2024-04-17
CO2024009334A2 (es) 2024-07-18
TW202340210A (zh) 2023-10-16
US20230234971A1 (en) 2023-07-27
KR20240136972A (ko) 2024-09-19
US20250066388A1 (en) 2025-02-27
EP4466273A1 (en) 2024-11-27
JP7714811B2 (ja) 2025-07-29
WO2023141536A1 (en) 2023-07-27
US11964990B2 (en) 2024-04-23
US20260028356A1 (en) 2026-01-29
CN119053610A (zh) 2024-11-29
JP2025160251A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
PH12021500017A1 (en) Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases
MX2026003002A (es) Inhibidores de kras
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2025010928A (es) Compuestos de alquinil quinazolina
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
MX2009004910A (es) Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo.
PH12022551767A1 (en) Sulfonimidamide compounds as nlrp3 modulators
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
MX2024013065A (es) Inhibidores de amida heterociclica biciclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor
PL369078A1 (en) Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
MX2024013095A (es) Compuestos inhibidores de fgfr2
ZA202212095B (en) Il4i1 inhibitors and methods of use
CA3242074A1 (en) 1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
MX2024008868A (es) Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
MX2025000174A (es) Compuestos y metodos terapeuticos.
MXPA05009688A (es) Derivados de naftiridina como agentes antibacterianos.
SE0302756D0 (sv) Novel Compounds
WO2003008412A3 (en) Hetero-bicyclic crf antagonists
PL374117A1 (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
MX2024005063A (es) Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos.
MX2025013372A (es) Inhibidores de gsk3\03b1 y metodos de uso de estos